Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...

After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major ...

This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelheim offered up to $991 million ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

In recognition of his contributions to viral vector–based therapeutics and translation, Dr. Curiel was elected a Fellow of the National Academy of Inventors. He is also a co-founder of biotech ...

Ottawa, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The global viral vector gene therapy market size was valued at USD 13.14 billion in 2024 and is predicted to hit around USD 38.39 billion by 2034, rising at a ...

Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of ...

Kacey puts her own spin on the latest popular TikTok trends. He Won the $2 Billion Powerball. Now He’s Buying Up Lots Burned in the L.A. Fires. Republicans have changed their minds on Ukraine ...